Key Highlights

● Keros will receive a $20 million milestone from Takeda after first patient dosing in the Phase 3 ELRiSE MF trial.

● Keros plans to distribute 25 percent of the net cash proceeds from the payment to its stockholders after receiving it.

● The milestone arises under a Takeda license effective January 16, 2025, which carries potential further milestones exceeding $1.1 billion.

● Keros received a $200 million upfront payment in February 2025, and the agreement also provides tiered royalties on net sales.

Keros Therapeutics, Inc. (NASDAQ:KROS) filed a Form 8-K on September 29, 2026, furnishing a press release headlined "Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda." The company will receive a $20 million development milestone from Takeda (NYSE:TAK), triggered by dosing of the first patient in the Phase 3 ELRiSE MF clinical trial of elritercept. The release also says Keros plans to distribute 25 percent of the net cash proceeds from the payment to its stockholders after it is received. The filing is made under Item 7.01 (Regulation FD Disclosure) and Item 9.01.

The Milestone and the Trial

A development milestone is a payment a licensee owes when a defined event in a drug's development occurs. Here the event is first patient dosing in ELRiSE MF, which the release describes as a Phase 3, multicenter, double-blind, randomized trial comparing the efficacy and safety of elritercept with placebo in patients with myelofibrosis who have anemia and are receiving concurrent ruxolitinib therapy. The release does not say when the payment is due to be received, and it does not state where the trial is enrolling.

Keros describes elritercept as an engineered ligand trap that combines a modified ligand-binding domain of a TGF-beta receptor with the Fc domain of a human antibody. According to the release, it is being developed to treat low blood cell counts, including anemia and thrombocytopenia, in myelodysplastic syndromes and myelofibrosis.

Jasbir S. Seehra, Ph.D., President and Chief Executive Officer of Keros, is quoted as calling the milestone another important step forward for the elritercept program and thanking Takeda for its dedication to bringing this potential new treatment to patients in need.

The Takeda Agreement

The milestone arises under a global license agreement with Takeda that took effect on January 16, 2025. It covers development, Manufacturing and commercialization of elritercept worldwide, excluding mainland China, Hong Kong and Macau. Keros received an upfront payment of $200 million in February 2025. The release says the agreement carries potential further milestone payments that exceed $1.1 billion, along with tiered royalties on net sales. This $20 million payment is one of those milestones, and the release does not itemize which other milestones remain or their timing.

The Planned Distribution to Stockholders

The most unusual element for an announcement of this kind is the plan to distribute a share of the proceeds. The release states that 25 percent of the net cash proceeds from this milestone payment will be distributed to stockholders following receipt. The release does not define "net," meaning which costs or taxes would be deducted, and it does not state the form of the distribution, the timing, the Record Date or the per-share amount. Those details, and any board action needed to authorize a distribution, are not in the filing.

On the arithmetic alone, a quarter of a $20 million payment would be $5 million before any deductions. That figure is a simple calculation, not a number stated by the company, and the actual amount depends on how the company defines net proceeds.

Like most company releases, this one carries cautionary language. It says the company's statements are subject to risks including its limited operating history, its funding needs, trial delays and competition. Because the payment and the distribution both concern future events, the release presents them as expectations.

Keros Awaits Takeda's $20 Million Elritercept Payment

The next items to look for are the receipt of the $20 million from Takeda and the company's announcement of the terms of the stockholder distribution, including its amount, timing and record date.